DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
about
Tandem mass spectrometry for characterization of covalent adducts of DNA with anticancer therapeuticsSulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104APronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumoursABC transporters in CSCs membranes as a novel target for treating tumor relapse.Targeting hypoxic tumour cells to overcome metastasis.Targeting hypoxia in the leukemia microenvironmentInitial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.Screening for DNA Alkylation Mono and Cross-Linked Adducts with a Comprehensive LC-MS(3) Adductomic ApproachHypoxia-activated prodrugs in cancer therapy: progress to the clinic.DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A.DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.Cytochrome P450-activated prodrugs.Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.Effect of hypoxia-inducible factors in normal and leukemic stem cell regulation and their potential therapeutic impact.Hypoxia-Sensitive Materials for Biomedical Applications.Photo-triggered fluorescent theranostic prodrugs as DNA alkylating agents for mechlorethamine release and spatiotemporal monitoring.Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.Aromatic nitrogen mustard-based prodrugs: activity, selectivity, and the mechanism of DNA cross-linking.Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures
P2860
Q28486298-8BABF59E-2ED5-4C9C-B3FA-3FAB0B9F849FQ28550585-4E1AB415-537D-4958-8B05-A2CDA57AAA62Q28741513-7C3079C8-72CB-454B-BA66-9A409628EEF8Q33395400-0AD10420-7C10-41C6-A6C3-1A29E2D91977Q33397528-82B443CE-5990-4B10-BEEA-D486BA8D40FEQ33404024-38F22237-E8B4-4A72-87AA-3180BAB33594Q33879326-C1535519-24C8-4547-AF9A-32129E5C71FCQ34086671-75EEE50F-ACD3-4D42-AAAA-28657792A542Q34401785-CF64746F-C5CD-4D72-B74A-CF316703EAE4Q35005290-BD76CB4F-3FFA-425F-98C3-7840107EF395Q36212847-FE29291D-9E81-480C-90F4-F2779F810749Q37217739-A42B0270-C1D5-413F-AC0B-4B9B5FA75A76Q37415654-392EB729-DEC3-4963-8AC9-C34E422B50B7Q37450078-99918614-ECBF-4C45-996B-80EA24253E0EQ37707385-BF718767-32CA-4697-8052-D29F5F6CB506Q37717094-529F8D95-D19F-436B-98AE-E817F6044359Q37736567-F65B6AA5-207F-4DDF-95BE-825A9489EC84Q38077550-163212F0-4560-427E-85EC-D49518549222Q38120850-E144C9E4-D9F6-473F-9B8A-BF4DD2EDD653Q38672565-B3030344-8CEB-42B8-97AD-C76DD2BAEE4AQ38754932-19BEA8E4-8F89-4C02-9C84-DF2FF5D0929AQ38872474-6B8E3686-375C-47D2-A976-58BE6E0E1A90Q39703345-3E376AA9-C385-44F6-91E6-94608561622AQ44502775-65FDC471-48B6-4AD2-8B43-F5772A7894BAQ44574765-505C1055-EF38-40B4-B31F-A6FE66B29D74Q57073801-3596EF52-1D3B-44D1-9D73-C74709D8AC04
P2860
DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
DNA cross-links in human tumor ...... metabolism, and cytotoxicity.
@ast
DNA cross-links in human tumor ...... metabolism, and cytotoxicity.
@en
DNA cross-links in human tumor ...... metabolism, and cytotoxicity.
@nl
type
label
DNA cross-links in human tumor ...... metabolism, and cytotoxicity.
@ast
DNA cross-links in human tumor ...... metabolism, and cytotoxicity.
@en
DNA cross-links in human tumor ...... metabolism, and cytotoxicity.
@nl
prefLabel
DNA cross-links in human tumor ...... metabolism, and cytotoxicity.
@ast
DNA cross-links in human tumor ...... metabolism, and cytotoxicity.
@en
DNA cross-links in human tumor ...... metabolism, and cytotoxicity.
@nl
P2093
P50
P1433
P1476
DNA cross-links in human tumor ...... e metabolism, and cytotoxicity
@en
P2093
Dianne M Ferry
J Martin Brown
Mary J Dorie
Susan M Pullen
William R Wilson
P304
P356
10.1158/0008-5472.CAN-08-4023
P407
P577
2009-04-14T00:00:00Z